Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk

Russell, Michelle; Carpenter, Mick; Akhtar, M S; Lagattuta, Theodore F.; Egorin, Merrill J.

doi:10.1038/sj.jp.7211665

Cited by 87 publications

(60 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 However, the mechanism of nutrient supply to the fetus varies at different stages in gestation. Prior to 10 weeks, there are no maternal arterial connections with the intervillous space, and during the first few weeks of development it is thought most likely that the embryo obtains nutrients by simple diffusion from blood pooled in the trophoblastic lacunae.…”

Section: Fetal Outcomementioning

confidence: 99%

The effects of imatinib on pregnancy outcome

Pye

Cortes

Ault

et al. 2008

Blood

316

197

View full text Add to dashboard Cite

Imatinib has now been in use for almost 10 years. Despite this cumulative experience, little is known about its effects on pregnancy; as a result, there are few published data to facilitate the counseling of women who conceive while taking imatinib. The results we now present provide information which may be of use in such circumstances. Of 180 women exposed to imatinib during pregnancy, outcome data are available for 125 (69%). Of those with known outcomes, 50% delivered normal infants and 28% underwent elective terminations, 3 following the identification of abnormalities. There were a total of 12 infants in whom abnormalities were identified, 3 of which had strikingly similar complex malformations that are clearly a cause for concern. It appears that although most pregnancies exposed to imatinib are likely to have a successful outcome, there remains a risk that exposure may result in serious fetal malformations. (Blood. 2008;111:5505-5508)

show abstract

Section: Fetal Outcomementioning

confidence: 99%

The effects of imatinib on pregnancy outcome

Pye

Cortes

Ault

et al. 2008

Blood

316

197

View full text Add to dashboard Cite

show abstract

“…It has been reported that the concentration of imatinib and its active metabolite were higher in the placenta than in the maternal blood, while they were low or undetected in the umbilical cord. These findings suggest limited placental transfer of imatinib in late pregnancy (Russell et al, 2007). It seems that administering imatinib during the first trimester is associated with a considerable risk of congenital anomalies and spontaneous abortions, while late exposure does not have the same impact.…”

Section: Chronic Leukemia In Pregnancy 521 Chronic Myelogenous Leukmentioning

confidence: 74%

Hematologic Malignancies in Pregnancy

Vandenbriele¹,

Vassou²,

Pentheroudakis³

et al. 2011

Acute Leukemia - The Scientist's Perspective and Challenge

View full text Add to dashboard Cite

“…592 There is evidence of increased fetal risk, and risk vs benefi t should be considered for use during pregnancy. 596 Animal studies suggest potential teratogenicity. 596 Imatinib can enter breast milk in animals and has been detected in breast milk in humans.…”

Section: -3 Months)mentioning

confidence: 99%

“…596 Animal studies suggest potential teratogenicity. 596 Imatinib can enter breast milk in animals and has been detected in breast milk in humans. 596 3.7.2.3 Monitoring-The manufacturer recommends a CBC count weekly for the fi rst month of therapy, biweekly for the second month, and then periodically.…”

Section: -3 Months)mentioning

confidence: 99%

See 1 more Smart Citation

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Baughman

Meyer

Nathanson

et al. 2012

Chest

View full text Add to dashboard Cite

Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and infl ammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols; monitoring to detect manifestations of toxicity; and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents. Methods: Committee members developed and refi ned a series of questions about toxicities of immunosuppressives and current approaches to administration and monitoring. A systematic review was carried out by the American College of Chest Physicians. Committee members were supplied with this information and created this evidence-based guideline. Conclusions: It is hoped that these guidelines will improve patient safety when immunosuppressive drugs are given to lung transplant recipients and to patients with diffuse interstitial lung disease. CHEST 2012; 142(5):e1S-e111SAbbreviations: ACCP 5 American College of Chest Physicians; ALT 5 alanine aminotransferase; ATG 5 antithymocyte globulin; CHF 5 congestive heart failure; CMV 5 cytomegalovirus; CNI 5 calcineurin inhibitor; COI 5 confl ict of interest; CsA 5 cyclosporin A; FDA 5 US Food and Drug Administration; HBV 5 hepatitis B virus; HMG-CoA 5 b -hydroxy-bmethylglutaryl-coenzyme A; HSP 5 Health and Science Policy Committee; IL2RA 5 IL-2 receptor a ; ILD 5 interstitial lung disease; IPF 5 idiopathic pulmonary fi brosis; ITP 5 idiopathic thrombocytopenia purpura; LAM 5 lymphangioleiomyomatosis; MESNA 5 sodium 2-sulfonylethanesufonate; MPA 5 mycophenolic acid; mTOR 5 mammalian target of rapamycin; PTLD 5 posttransplant lymphoproliferative disease; RCT 5 randomized controlled trial; SIRS 5 systemic infl ammatory response syndrome; TNF 5 tumor necrosis factor; TPMT 5 thiopurine methyltransferase

show abstract

Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk

Cited by 87 publications

References 17 publications

The effects of imatinib on pregnancy outcome

The effects of imatinib on pregnancy outcome

Hematologic Malignancies in Pregnancy

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Contact Info

Product

Resources

About